BioInsights - Driving disruptive innovation in the ATMP field

Driving disruptive innovation in the ATMP field

Cell & Gene Therapy Insights 2020; 6(9), 1263–1269


Published: 6 October 2020
Kerstin Papenfuss

Kerstin Papenfuss started her PhD at German Cancer Research Centre and then moved to a lab at Imperial College London to work on novel treatment options within the field of tumor immunology. After a Post Doc in academic drug discovery, she since has spent almost ten years in leadership roles at impact-driven organizations advancing medicine and therapeutics, while also securing an executive MBA and a Women in Business award. Before joining DSV to develop science companies designing more effective therapies, Kerstin was transforming ideas for cutting edge cell and gene therapies into investable propositions at UK’s Cell and Gene Therapy Catapult.